EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Elastase Inhibitor ShSPI from Centipede Attenuates Bleomycin-Induced Pulmonary Fibrosis

Xi Lian, Bin Liu, Dan Li, Xinyao Wang, Chengbo Long, Xing Feng iD, Qiong Liao, Mingqiang Rong

Toxins · 2025

DOI: 10.3390/toxins17050213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2025. Verfasst von Xi Lian und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Hunan Normal University, Changsha 410004, China. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pancreatic Elastase, Pulmonary Fibrosis, Anti-Inflammatory Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, National Key R&D Program of China, Department of Science and Technology of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterized by the fibrotic thickening of the alveolar walls, resulting in compromised gas exchange, restricted ventilation, and respiratory failure. It has been indicated that elastase inhibitors reduced the severity of IPF by neutralizing excessive elastase levels in the lungs. ShSPI is an elastase inhibitor derived from centipede toxin. The present study evaluates the therapeutic effects of ShSPI in a bleomycin-induced idiopathic pulmonary fibrosis model. According to the results, ShSPI markedly reduced the weight loss, showing the improvement of health status in bleomycin-induced mice. Its robust antifibrotic effects were evidenced by the mitigation of alveolar structural damage, reduction in inflammatory cell infiltration, inhibition of collagen deposition, and suppression of fibrotic nodule formation. ShSPI effectively attenuated inflammatory responses by downregulating pro-inflammatory factors (IL-6, IL-1β, and MCP-1) and upregulating the anti-inflammatory factor interleukin-10 (IL-10). After delivered via inhalation, ShSPI exhibited favorable pharmacokinetic properties. It could be detected at 8 h at doses of 1 mg/kg and achieved maximum plasma concentrations (Cmax) of 188.00 ± 64.40 ng/mL in vivo. At high doses (160 mg/kg), ShSPI maintained a strong safety profile, with no detectable toxicity observed. This feature shows the therapeutic potential of ShSPI in the treatment of idiopathic pulmonary fibrosis and provides valuable evidence for its development as a novel peptide-based therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisPancreatic ElastasePulmonary FibrosisAnti-Inflammatory AgentsAnimalsBleomycinMaleLungMiceMice, Inbred C57BLCytokinesDisease Models, Animal

Stichwörter der Autor:innen

ShSPIcentipedeelastaseidiopathic pulmonary fibrosis (IPF)inflammatory factorsneutrophils

Substanzen

BleomycinPancreatic ElastaseCytokinesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • College of Life Sciences, Hunan Normal University, Changsha 410004, China.
  • Chengdu PDBio Co., Ltd., Chengdu 610225, China.
  • Key Laboratory of Study and Discovery of Small Targeted Molecules of School of Pharmaceutical Sciences, Hunan Normal University, Changsha 410013, China.
  • Hunan Provincial Key Laboratory of Animal Intestinal Function and Regulation, Hunan Normal University, Changsha 410004, China.
  • The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 410004, China.

ORCID-Profile: Xing Feng

Förderung

  • Natural Science Foundation of Hunan Province
  • National Key R&D Program of China
  • Department of Science and Technology of Sichuan Province
  • National Students' Platform for Innovation and Entrepreneurship Training Program
  • National Key R&D Program of China
  • National Students’ Platform for Innovation and Entrepreneurship Training Program
  • Hunan Provincial Health Commission
  • Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs, the third hospital of Changsha

Zitieren

APA

Lian, X., Liu, B., Li, D., Wang, X., Long, C., Feng, X., Liao, Q., & Rong, M. (2025). An Elastase Inhibitor ShSPI from Centipede Attenuates Bleomycin-Induced Pulmonary Fibrosis. Toxins. https://doi.org/10.3390/toxins17050213

Vancouver

Lian X, Liu B, Li D, Wang X, Long C, Feng X, et al. An Elastase Inhibitor ShSPI from Centipede Attenuates Bleomycin-Induced Pulmonary Fibrosis. Toxins. 2025. doi:10.3390/toxins17050213

BibTeX
@article{Lian2025,
  author = {Lian, Xi and Liu, Bin and Li, Dan and Wang, Xinyao and Long, Chengbo and Feng, Xing and Liao, Qiong and Rong, Mingqiang},
  title = {An Elastase Inhibitor ShSPI from Centipede Attenuates Bleomycin-Induced Pulmonary Fibrosis},
  journal = {Toxins},
  year = {2025},
  doi = {10.3390/toxins17050213}
}
Kostenlos starten →